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Tuberculosis remains a major public health challenge for India. Various studies have docu-
mented different levels of TB and multi-drug resistant (MDR) TB among diverse groups of
the population. In view of renewed targets set under the End TB strategy by 2035, there is
an urgent need for TB diagnosis to be strengthened. Drawing on data from a recent, multi-
site study, we address key questions for TB diagnosis amongst symptomatics presenting
for care: are there subgroups of patients that are more likely than others, to be positive for
TB? In turn, amongst these positive cases, are there factors—apart from treatment history
—that may be predictive for multi-drug resistance?
Methods
We used data from a multi-centric prospective demonstration study, conducted from March
2012 to December 2013 in 18 sub-district level TB programme units (TUs) in India and cov-
ering a population of 8.8 million. In place of standard diagnostic tests, upfront Xpert MTB/
RIF testing was offered to all presumptive TB symptomatics. Here, using data from this
study, we used logistic regression to identify association between risk factors and TB and
Rifampicin-Resistant TB among symptomatics enrolled in the study.
Results
We find that male gender; history of TB treatment; and adult age compared with either chil-
dren or the elderly are risk factors associated with high TB detection amongst sympto-
matics, across the TUs. While treatment history is found be a significant risk factor for
rifampicin-resistant TB, elderly (65+ yrs) people have significantly lower risk than other age
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groups. However, pediatric TB cases have no less risk of rifampicin resistance as compared
with adults (OR 1.23 (95% C.I. 0.85–1.76)). Similarly, risk of rifampicin resistance among
both the genders was the same. These patterns applied across the study sites involved.
Notably in Mumbai, amongst those patients with microbiological confirmation of TB, female
patients showed a higher risk of having MDR-TB than male patients.
Conclusion
Our results cast fresh light on the characteristics of symptomatics presenting for care who
are most likely to be microbiologically positive for TB, and for rifampicin resistance. The
challenges posed by TB control are complex and multifactorial: evidence from diverse
sources, including retrospective studies such as that addressed here, can be invaluable in
informing future strategies to accelerate declines in TB burden.
Background
Tuberculosis (TB) is one of the world’s deadliest communicable diseases. Of the estimated 9.6
million new TB cases in 2014, India alone accounted for 23% of total cases [1]. While most
cases of TB are curable with cost-effective combination chemotherapy, multi-drug-resistant
(MDR) TB is becoming an increasing challenge, accounting for an estimated 480,000 cases
globally in 2014, of whom only 123,000 were detected. Treatment for MDR-TB is costly and
protracted, and shows substantially lower success rates than for drug-sensitive TB. In India
alone there are an estimated 64,000 MDR-TB cases occurring annually among notified pulmo-
nary TB cases [2]. Drug resistance surveys in several states suggest that the prevalence of MDR
TB in India is 2–3 percent among new cases and 12–17 percent among reinfection cases [3].
Although TB and MDR TB detection and notification rates have seen recent improvements,
to achieve the global target set under the End TB strategy [4], there is a need to intensify case
detection of TB and drug-resistant TB.
Typically in India and elsewhere, patients referred to the national TB programme for diag-
nosis are those showing symptoms that are suggestive, but not necessarily definitive, for TB dis-
ease (symptoms such as chronic cough, fever and weight loss). These patients, ‘presumptive TB
symptomatics’, are offered microbiological testing for TB, most often using smear microscopy:
an affordable and well-established diagnosis, that nonetheless can miss upto half of TB cases.
Detection of drug resistance offers additional challenges, being a resource- and time- intensive
procedure that is currently offered only to specific risk groups, primarily those with a history
of TB treatment. Given such limitations, therefore, there has been considerable uncertainty
around the predictors of TB and MDR-TB in the symptomatic population. That is: are there
subgroups amongst presumptive TB symptomatics that are more likely than others, to be posi-
tive for TB? In turn, amongst these positive cases, are there factors—apart from treatment his-
tory—that may be predictive for multi-drug resistance?
In the present study we aim to address these questions by taking advantage of a recent large,
multi-site study in India where presumptive TB symptomatics were offered high-sensitivity,
rapid molecular testing, in place of existing diagnostic tests. Casting fresh light on TB and
MDR-TB cases in the symptomatic population,that might otherwise have been missed by
smear microscopy, this data provides a unique opportunity for identifying patient factors to
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guide prioritization of diagnosis efforts. Moreover, previously unrecognised patient factors
may merit further investigation, for their potential epidemiological importance.
Methods
We drew from a recent multi-centric prospective demonstration study conducted by FIND
(Foundation for Innovative New Diagnostics), which enrolled more than 100,000 presumptive
TB symptomatics, under programmatic conditions, across 18 diverse settings from March’12
to December’13 [5]. In place of existing diagnostic tests, upfront Xpert MTB/RIF testing was
provided to all TB symptomatics seeking care; high levels of TB and MDR TB were reported
[5]. The 18 sites were purposively selected based on the availability of free treatment for
patients diagnosed with rifampicin resistance, and to represent diverse geographic and demo-
graphic settings across the country. Of these, 8 sites were in rural areas catering to a population
of 3.9 million, 6 sites were in urban areas catering to a population of 3.4 million and 4 sites
were in tribal and hilly area covering a population of 1.5 million. Altogether, these 18 sites
account for 8.8 million people having access to TB diagnostic services. As in any programmatic
setting in India, presumptive TB symptomatics were referred by a range of providers, together
representing a range of healthcare settings from primary care to inpatient settings. Further
details on the study design are given elsewhere [5].
The study protocol was approved by the Institution Ethics Committee of the National
Tuberculosis Institute, Bangalore, India. Structured informed consent forms were used for
obtaining written consent from all subjects enrolled in the study. Before taking consent,
patients were informed about the study in vernacular language by the trained staff. For illiterate
patients, consent was taken in presence of literate witness; similarly written consent for the
children less than 18 years of age was obtained from the parents / guardians accompanying
them. Approval for the study was granted by the Central TB Division, Ministry of Health and
Family Welfare, Government of India.
In the present work, data analysis was performed using logistic regression to identify factors
associated with two separate outcomes: (i) bacteriologically positive TB (i.e. Xpert positive)
amongst all cases receiving a GeneXpert test, and (ii) Rifampicin resistance (again as diagnosed
by Xpert), amongst all patients testing positive for TB. We considered five covariates from the
available data that were specified prior to conducting the analysis: gender (Male or Female);
Age (upto 15 yrs; 16–64 yrs and 65 yrs+); history of prior TB treatment (yes or no); the type of
provider (public sector; private provider; medical college; non- governmental organizations
(NGO); and anti-retroviral treatment (ART) centre), and the geographical area (rural, urban,
and tribal or hilly). In particular, denoting these patient characteristics respectively as XGender,
XAge, XHistory, XProvider and XArea, we fitted the model:
logit YTB ¼ b0 þ bGender XGender þ bAgeXAge þ bHistoryXHistory þ bProviderXProvider þ bAreaXArea;
where YTB is the probability of a symptomatic patient being positive for TB. Amongst those
patients testing positive for TB, we similarly ﬁtted the model:
logit YMDR j TB ¼ b0 þ bGender XGender þ bAgeXAge þ bHistoryXHistory þ bProviderXProvider þ bAreaXArea;
where YMDR | TB is the probability of a conﬁrmed TB case having MDR-TB. Because Mumbai
(an urban site in Maharashtra state) has a unique TB epidemic [6–7], with high levels to rifam-
picin resistant reported and also observed in our dataset, we stratiﬁed the analysis to consider
Mumbai data separately from the other locations. All analyses were performed in the statistical
analysis software R.
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Results
Under the study, a total of 1, 04, 276 presumptive TB cases were enrolled, of which 22,686
(21.8%) were diagnosed with TB and out of them 2,765 (2.7%) were found to be resistant to
rifampicin. (Table 1)
Table 2 shows the results of the multivariable analysis, for factors associated with bacterio-
logically positive TB case detection. Risk factors that are consistent across the TUs include:
male gender; history of TB treatment; adult age compared with either children or the elderly;
type of provider, and geographical location. Importantly, TB symptomatics referred from ART
centers had a lower rate of TB detection compared to patients referred by the public sector.
Moreover, in Mumbai results suggest a higher rate of bacteriologically positive TB amongst
patients referred by private providers, medical colleges and NGOs, compared to those referred
by the public sector, while in other TUs, there is a higher rate amongst patients referred by pri-
vate providers, medical colleges and ART centres.
Table 3 shows results for factors associated with rifampicin resistance, amongst diagnosed
TB cases. As would be expected, treatment history is a significant risk factor for rifampicin
resistance, both in Mumbai and in other TUs. While the elderly (65+ yrs) have significantly
lower risk than other age groups, there is no evidence that pediatric TB cases have any smaller
risk of rifampicin resistance than adults, in any of the sites in this study (OR 1.23 (95% C.I.
0.85–1.76)).
Results also suggest notable risk patterns by sex: in sites other than Mumbai, female TB
cases have no significant difference in rates of rifampicin resistance compared to male TB
patients. In Mumbai, by contrast, female TB cases are significantlymore at risk of rifampicin
resistance than male cases. As this result arises after adjusting for age, treatment history, and
referring provider in the multivariable analysis, it is not necessarily due, for example, to higher
levels of treatment history amongst females. Indeed, regressing treatment history against sex
suggested a lower rate of treatment history amongst female vs male cases in Mumbai (odds
ratio 0.89 (95% CI 0.84–0.93)).
Finally, there appears again to be a role for the treating provider, with TB cases being catered
by private providers and medical colleges having a greater risk of being rifampicin-resistant,
across all TUs, than those referred by the public sector.
Discussion
To meet the renewed global targets in TB control, there is a pressing need for a better under-
standing of specific groups that bear a disproportionate TB burden. Here we have taken advan-
tage of findings from a recent, large-scale GeneXpert demonstration study, to explore patient
characteristics associated with diagnosis for TB and for Rifampicin resistance. While this work
cannot by itself offer conclusive evidence for causal associations, results could point the way
for further, in-depth analysis wherever hitherto unexpected associations emerge. Such analysis
could provide a first step, either in identifying specific groups for targeting in future case-find-
ing, or in determining risk factors that may be amenable to intervention.
Several factors identified by this analysis are consistent with what is already understood
about TB burden: for example, higher TB diagnosis rates in male than female TB symptomatics
being in agreement with the higher prevalence of TB in men [8]. Moreover, a lower risk of TB
and MDR-TB amongst the elderly, compared to other age groups, may be due to reduced sur-
vival amongst those with TB infection [9].
However, some findings in particular suggest hitherto unrecognized risk factors. First,
results (Table 3) suggest that rates of drug resistance amongst bacteriologically positive, pediat-
ric cases are as high as in adults, across all of the sites involved. Owing to the challenges around
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bacteriological confirmation of pediatric TB, a major proportion of childhood TB cases are
diagnosed clinically and initiated on first line TB treatment [10–11]. This makes laboratory
diagnosis of drug-resistance in the pediatric population quite challenging. Our analysis sug-
gests a need for strengthened drug-resistance surveillance in pediatric patients diagnosed with
TB and/ or potentially reviewing the diagnostic and treatment strategy in presumptive pediat-
ric TB. Second, despite a higher TB prevalence in males than females, TB cases of both genders
show, overall, a similar risk of having MDR-TB. Indeed, in Mumbai the risk is greater amongst
females than males, even when adjusting for treatment history, age and other factors. Risks of
active TB among infected people are similar in both sexes in scenarios where the transmission
rates are high [12–15]. A higher proportion of rifampicin resistance in female cases in Mumbai
could point towards higher transmission of rifampicin resistance in that population. Although
it remains unclear why this appears to be specific to Mumbai, the TB epidemic in Mumbai
stands apart in other respects too. The city contains the largest slum in the world, and available
evidence points to an MDR-TB epidemic in Mumbai that is more extensive than anywhere else
in the country [6–7]. There is increasing recognition for the need to identify the key drivers
behind this epidemic [16] such efforts may also cast valuable light on the patterns observed in
the current study.
Our results also suggest some associations with respect to the referring provider: for exam-
ple, Over 27% of HIV-positive TB symptomatics in this population were bacteriologically posi-
tive for TB (higher than 13% amongst smear-positive symptomatics) [17]. In the present
analysis, however, the odds of TB detection amongst patients referred from ART centres is
lower than those referred by the public sector. A potential explanation is that ART centres may
simply be referring symptomatics more readily than in the public sector. Conversely, selective
Table 1. Demographic profile of study participants.
N % (of N) TB % (of row) Rif- Resistance % (of row)
Total 1,04,276 100 22,686 21.8% 2,765 2.7%
Gender
Female 38,384 36.8 6,686 17.4% 1,027 2.7%
Male 65,892 63.2 16,000 24.3% 1,738 2.6%
Past history of anti TB treatment
Previous TB 20,615 19.8 8,125 39.4% 1,912 9.3%
New 83,255 79.8 14,561 17.5% 853 1.0%
Age category (Years)
Child 4,647 4.5 514 11.1% 91 2.0%
Adult 80,655 77.3 19,137 23.7% 2,490 3.1%
Elderly 18,974 18.2 3,035 16.0% 184 1.0%
Provider
Public 78,740 75.5 16,591 21.1% 1,443 1.8%
Private 2,738 2.6 757 27.6% 138 5.0%
Med. college 16,453 15.8 4,273 26.0% 1,102 6.7%
NGO 4,903 4.7 815 16.6% 62 1.3%
ART centre 1,442 1.4 250 17.3% 20 1.4%
Settings
Mumbai 12,041 11.5 3,454 28.7% 1,233 10.2%
Urban (excl. Mumbai) 36,787 35.3 8,173 22.2% 806 2.2%
Rural 40,832 39.2 7,964 19.5% 496 1.2%
Tribal/hilly 14,616 14.0 3,095 21.2% 230 1.6%
doi:10.1371/journal.pone.0150054.t001
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referral may explain why patients referred from the private sector and medical colleges were
more likely to be diagnosed with TB than those from the public sector. Rifampicin resistance is
higher amongst patients referred by the private sector than those referred by the public sector,
perhaps suggestive of lower treatment quality in the private sector [18–19]. However, medical
colleges also show higher rates of resistance: with quality of care in this sector likely to be
higher than amongst private providers, a potential explanation is that medical colleges may
tend to receive TB cases who have not responded to treatment elsewhere. Unfortunately it was
not possible, with the available data, to explore further the potential role of these risk factors by
provider.
Our study has other limitations to note. First, a true prevalence survey would aim to detect
cases in the community, including those that have not sought care. Our analysis, by contrast, is
based on TB symptomatics as a study population. Our results are therefore relevant to risk fac-
tors amongst presumptive TB symptomatics, as opposed to factors in the general population.
Nonetheless, they cast light on potentially important factors for case finding in the general pop-
ulation,that merit further investigation. Secondly, while we adjusted in our analysis for key
Table 2. Predictors of TB positivity amongst all TB symptomatics. Owing to the size of the dataset, all associations shown as significant have p < 10−5,
with the exception of Mumbai patients referred by ART centres (p = 0.01).
Predictor Levels Odds ratio, unadjusted (95% C.I.) Odds ratio, adjusted (95% C.I.)
Mumbai TU
Sex Female 0.84 (0.77, 0.91) 0.85 (0.79, 0.93)
Male Reference Reference
HXTB Previous history 2.4 (2.22, 2.61) 2.22 (2.05, 2.42)
No previous history Reference Reference
Age Child 0.42 (0.35, 0.5) 0.49 (0.4, 0.59)
Adult Reference Reference
Elderly 0.56 (0.48, 0.65) 0.56 (0.48, 0.65)
Provider Private 2.19 (1.85, 2.59) 1.95 (1.65, 2.32)
Medical College 1.52 (1.4, 1.66) 1.32 (1.21, 1.43)
NGO 1.51 (1.1, 2.06) 1.57 (1.13, 2.16)
ART Centre 0.59 (0.32, 1.01) 0.47 (0.25, 0.82)
Public Reference Reference
Other TUs
Sex Female 0.61 (0.58, 0.63) 0.62 (0.6, 0.65)
Male Reference Reference
HXTB Previous history 3.06 (2.95, 3.18) 2.92 (2.81, 3.03)
No previous history Reference Reference
Age Child 0.37 (0.33, 0.41) 0.43 (0.38, 0.48)
Adult Reference Reference
Elderly 0.63 (0.61, 0.66) 0.6 (0.57, 0.63)
Provider Private 1.3 (1.17, 1.45) 1.38 (1.23, 1.53)
Medical College 1.19 (1.13, 1.25) 1.11 (1.06, 1.17)
NGO 0.76 (0.71, 0.83) 0.94 (0.87, 1.02)
ART Centre 0.79 (0.68, 0.9) 0.69 (0.59, 0.79)
Public Reference Reference
Area Tribal & Hilly 1.15 (1.1, 1.2) 1.11 (1.06, 1.17)
Urban 1.2 (1.16, 1.25) 1.07 (1.03, 1.11)
Rural Reference Reference
doi:10.1371/journal.pone.0150054.t002
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variables, residual confounding may remain. As such, any associations identified by this analy-
sis should not be interpreted as causal analysis. More in-depth investigation is needed to
explain the phenomenon of female TB cases in Mumbai having higher rates of drug resistance
than male TB cases. Likewise, the role of the referring provider is an important subject for
future work.
Conclusion
In summary, the challenges posed by TB control are complex and multifactorial: evidence from
diverse sources, including retrospective studies such as that addressed here, can be invaluable
in informing future strategies to accelerate declines in TB burden.
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Table 3. Risk groups for Rifampicin resistance amongst Xpert positive cases. As in Table 2, all significant associations have p < 10−5, with the excep-
tions of: Mumbai patients referred by the private sector (p = 0.01) and by NGOs (p = 0.001).
Predictor Levels Odds ratio, unadjusted (95% C.I.) Odds ratio, adjusted (95% C.I.)
Mumbai TU
Sex Female 1.53 (1.33, 1.76) 1.5 (1.29, 1.74)
Male Reference Reference
HXTB Previous history 2.86 (2.48, 3.32) 2.85 (2.46, 3.31)
No previous history Reference Reference
Age Child 1.38 (0.98, 1.93) 1.23 (0.85, 1.76)
Adult Reference Reference
Elderly 0.65 (0.47, 0.87) 0.65 (0.48, 0.89)
Provider Private 1.4 (1.06, 1.85) 1.44 (1.07, 1.91)
Medical College 2.03 (1.74, 2.36) 1.82 (1.56, 2.13)
NGO 2.54 (1.5, 4.27) 2.41 (1.4, 4.13)
ART Centre 0.45 (0.07, 1.67) 0.35 (0.05, 1.34)
Public Reference Reference
Other TUs
Sex Female 1.06 (0.95, 1.19) 1.12 (0.99, 1.26)
Male Reference Reference
HXTB Previous history 5.49 (4.91, 6.16) 5.6 (4.99, 6.3)
No previous history Reference Reference
Age Child 0.9 (0.6, 1.3) 0.95 (0.62, 1.4)
Adult Reference Reference
Elderly 0.49 (0.4, 0.59) 0.54 (0.44, 0.65)
Provider Private 1.4 (1.02, 1.89) 1.89 (1.36, 2.58)
Medical College 2.23 (1.96, 2.53) 2.26 (1.96, 2.59)
NGO 0.61 (0.42, 0.85) 0.93 (0.63, 1.32)
ART Centre 1.09 (0.65, 1.73) 1.32 (0.78, 2.12)
Public Reference Reference
Area Tribal & Hilly 1.21 (1.03, 1.42) 1.18 (0.99, 1.39)
Urban 1.65 (1.47, 1.85) 1.08 (0.95, 1.23)
Rural Reference Reference
doi:10.1371/journal.pone.0150054.t003
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